ipilimumab,nivolumab,durvalumab,paclitaxel,vinorelbine,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['lcsm,(-blcsm)', 'durva', 'nsclc', 'aegean', 'cm816', 'sclc']
aegean: neoadjuvant durvalumab + chemo followed by adjuvant durva in resectable stage iia-iiib(n2) nsclc, a double-blind study by dr. john heymach. similar pcr and efs to cm816 (neo-adj only, open-label). still with immature follow-up (11.7mo) and events (31.9%). #aacr23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC